Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
12:00am, Tuesday, 14'th Jul 2020
Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall h
Inventiva S A : annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris | Zone bourse
12:30pm, Friday, 10'th Jul 2020Inventiva S A : annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris | Zone bourse
06:00am, Friday, 10'th Jul 2020The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
12:00am, Thursday, 09'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Akero Therapeutics Inc (...
CytoDyn: Bears Bring Out Their Champion To Take On The Army Of Bulls (OTCMKTS:CYDY)
08:46pm, Wednesday, 08'th Jul 2020
CytoDyn’s stock is under selling pressure following a short-centric report from the notorious Citron Research.
Biogen Stock Is Jumping. The Biotech Submitted Its Troubled Alzheimer’s Drug for FDA Approval.
02:13pm, Wednesday, 08'th Jul 2020
Biogen has finished submitting its application for approval for aducanumab to the Food and Drug Administration. That submission was originally expected to be completed in early 2020.
Better Coronavirus Stock: Altimmune vs. Vaxart | The Motley Fool
10:40am, Wednesday, 08'th Jul 2020
Both of these small-cap vaccine stocks are up big in 2020.
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
12:15am, Wednesday, 08'th Jul 2020
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall h
89bio Announces Pricing of Upsized Public Offering of Common Stock
12:00am, Wednesday, 08'th Jul 2020
SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
Poxel : nombre d’actions et de droits de vote composant le capital social
12:00am, Tuesday, 07'th Jul 2020
Regulatory News: Poxel (Paris:POXEL) : Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement G
IPO Update: Inventiva SA Looks For $102 Million U.S. IPO (Pending:IVA)
09:58pm, Monday, 06'th Jul 2020
Inventiva SA has filed proposed terms for a U.S. IPO of $102 million.
